MaRS Innovation selects umbilical cord stem cell technology from Samuel Lunenfeld Resea... - 0 views
www.marsdd.com/...ommercialization-06292009.html
healthcare MaRS Innovation Rafi Hofstein Samuel Lunenfeld Research Institute Mount Sinai Hospital
![](/images/link.gif)
-
MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.
-
With the Toronto area identified as a world-leading cluster in stem cell research, we are extremely excited to have identified this technology as our first commercialization opportunity,” said Dr. Rafi Hofstein, President and CEO of MaRS Innovation.
-
MaRS Innovation, along with the inventors and Mount Sinai, will initially focus on the diabetes application for the technology, as research has demonstrated that these cells uniquely secrete insulin in response to glucose, thereby mimicking the “normal” physiological state.
- ...5 more annotations...
-
The technology – invented by Mount Sinai scientists Dr. Ian Rogers and Dr. Robert Casper – offers a proprietary method to create multi-potent stem cells (MPSCs) from human umbilical cord blood.
-
Our partnership with MaRS Innovation on developing methods for using stem cells for diseases such as diabetes will allow us to work towards advancing care for these critical conditions." With the launch of this first exciting opportunity, MaRS Innovation has embarked on a journey to transform the Toronto-based research enterprise into a successful commercialization cluster.
-
MaRS Innovation is building its own internal infrastructure to support intellectual property and market due diligence to identify the most promising commercial opportunities. MaRS Innovation is dedicated to converting the outstanding science of its member institutions into products and services, making a significant contribution to Canada’s future economic outlook and the quality of life for Canadians and others around the world
-
“We are deeply committed to creating a powerful engine for commercialization that brings together an experienced team to identify and validate market opportunities, develop technologies to market requirements and build the linkages that will advance the exceptional research of all of our institutional members,” added Dr. Hofstein. “We look forward to announcing additional technologies to add to our pipeline over the next several weeks.”
-
MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are announce that they have entered into an agreement to collaboratively initiate commercialization of an umbilical cord stem cell technology for potential treatment in cardiovascular disease, diabetes and neurological disorders.